Combination therapy of antibodies activating human CD40 and antibodies against human PD-L1

The present disclosure relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-LI antibody; and optionally a 3

Saved in:
Bibliographic Details
Main Authors Stern, Martin, Corse, Emily Rana, Le Clech, Marine, Gerdes, Christian, Ott, Marion, Wei, Xu, Freytag, Olivier, Levitsky, Hyam
Format Patent
LanguageEnglish
Published 15.12.2016
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-LI antibody; and optionally a 3
Bibliography:Application Number: AU20150303239